NYVAC: A highly attenuated strain of vaccinia virus

Tartaglia, James; Perkus, Marion E.; Taylor, Jill; Norton, Elizabeth; Audonnet, Jean-Christophe; Cox, William I.; Davis, Stephen W.; Hoeven, Johanna Van Der; Meignier, Bernard; Rivière, M.; Languet, B.; Paoletti, Enzo

doi:10.1016/0042-6822(92)90752-b

Cited by 433 publications

(269 citation statements)

References 41 publications

Supporting

Mentioning

267

Contrasting

Order By: Relevance

“…However, between 5 and 7 days post-injection, mice showed typical cutaneous pox lesions on the tail and footpad (data not shown). This is characteristic of VV 43 and the necrotic skin lesion healed slowly and completely over the course of 6 weeks.…”

Section: Oncolytic Vaccinia Virus Expressing Fcu1 J Foloppe Et Almentioning

confidence: 84%

“…27,34,40 Recombinants of the Copenhagen strain of VV have been shown to be 5000 times less virulent than the strain WR when injected intracranially into 3-week-old mice and it is better tolerated by nude mice. 43 Furthermore, the vaccine Copenhagen strain was approved for human vaccine use in Denmark and the Netherlands. 44 A recombinant of the Copenhagen strain expressing the rabies virus glycoprotein was constructed by the insertion of the encoding cDNA in the TK locus.…”

Section: Oncolytic Vaccinia Virus Expressing Fcu1 J Foloppe Et Almentioning

confidence: 99%

See 1 more Smart Citation

Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus

et al. 2008

View full text Add to dashboard Cite

We have generated a thymidine kinase gene-deleted vaccinia virus (VV) (Copenhagen strain) that expressed the fusion suicide gene FCU1 derived from the yeast cytosine deaminase and uracil phosphoribosyltransferase genes. Intratumoral inoculation of this thymidine kinase genedeleted VV encoding FCU1 (VV-FCU1) in the presence of systemically administered prodrug 5-fluorocytosine (5-FC) produced statistically significant reductions in the growth of subcutaneous human colon cancer in nude mice compared with thymidine kinase gene-deleted VV treatments or with control 5-fluorouracil alone. A limitation of prodrug therapies has often been the requirement for the direct injection of the virus into relatively large, accessible tumors. Here we demonstrate vector targeting of tumors growing subcutaneously following systemic administration of VV-FCU1. More importantly we also demonstrate that the systemic injection of VV-FCU1 in nude mice bearing orthotopic liver metastasis of a human colon cancer, with concomitant administration of 5-FC, leads to substantial tumor growth retardation. In conclusion, the insertion of the fusion FCU1 suicide gene potentiates the oncolytic efficiency of the thymidine kinase gene-deleted VV and represents a potentially efficient means for gene therapy of distant metastasis from colon and other cancers.

show abstract

Section: Oncolytic Vaccinia Virus Expressing Fcu1 J Foloppe Et Almentioning

confidence: 84%

Section: Oncolytic Vaccinia Virus Expressing Fcu1 J Foloppe Et Almentioning

confidence: 99%

Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus

et al. 2008

View full text Add to dashboard Cite

show abstract

“…The CD4 + T-cell-replacement activity of CD40L in our DC co-culture experiments is especially intriguing in the setting of development of a therapeutic vaccine for HIV-1. One advantage of canarypox vector is its high-profiled safety, which has been demonstrated in both animal studies and clinical trials [5,9,29,48]. Another advantage of canarypox vector is that as a DNA virus that can only abortively infect mammalian cells, the target gene will be expressed transiently, which may be especially important for the expression of costimulatory molecules, such as CD40L, since long-term presence of costimulatory molecules might lead to autoimmunity or immunosuppression [49][50][51].…”

Section: Discussionmentioning

confidence: 99%

“…ALVAC is an attenuated canarypox derived vector that cannot replicate productively in mammalian cells [5,6]. ALVAC HIV-1 vaccine is a candidate HIV-1 vaccine, which is now in Phase III clinical trials [7,8] (http://www.iavireport.org/specials/OngoingTrialsofPreventiveHIVVaccines.pdf).…”

Section: Introductionmentioning

confidence: 99%

CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals

Liu

Stone

et al. 2008

Vaccine

View full text Add to dashboard Cite

SummaryHuman immunodeficiency virus-1 (HIV-1) canarypox vaccines are safe but poorly immunogenic. CD40 ligand (CD40L), a member of the tumor necrosis factor superfamily (TNFSF), is a pivotal co-stimulatory molecule for immune responses. To explore whether CD40L can be used as an adjuvant for HIV-1 canarypox vaccine, we constructed recombinant canarypox viruses expressing CD40L. Co-immunization of mice with CD40L expressing canarypox and the canarypox vaccine expressing HIV-1 proteins, vCP1452, augmented HIV-1 specific cytotoxic T lymphocyte (CTL) responses in terms of frequency, polyfunctionality and interleukin (IL)-7 receptor α chain (IL-7Rα, CD127) expression. In addition, CD40L expressed from canarypox virus could significantly augment CD4 + T cell responses against HIV-1 in mice. CD40L expressed from canarypox virus matured human monocyte-derived dendritic cells (MDDCs) in a tumor necrosis factor α (TNF-α) independent manner, which underwent less apoptosis, and could expand ex vivo Epstein-Barr virus (EBV)-specific CTL responses from healthy human individuals and ex vivo HIV-1-specific CTL responses from HIV-1-infected individuals in the presence or absence of CD4 + T cells. Taken together, our results suggest that CD40L incorporation into poxvirus vectors could be used as a strategy to enhance their immunogenicity.

show abstract

“…Such concern is caused by: the human pathogenicity of vaccinia which may have been underestimated in the past, the lack of a suitable model for human virulence, the wide host range of vaccinia virus, the potential dangers of using a live vaccine in populations in which HIV has a high incidence, and the possibility that the recombinant could become established in wildlife and even interact with other orthopoxviruses [12, 13,15,16]. Adequate attenuation of the vaccinia vectors is essential, and further highly attenuated vaccinia recombinants with limited replication potential are being developed by specific deletion of genes concerned with host range and virulence functions [6,17].…”

Section: Poxvirus Recombinant Vaccinesmentioning

confidence: 99%